贝伐单抗联合化疗治疗晚期结直肠癌的临床探讨

Clinical observation of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer

目的探讨贝伐单抗联合化疗治疗晚期结直肠癌的临床效果及毒副作用。方法随机选取2010年10月—2014年7月在该院治疗的晚期结直肠癌患者,均给予贝伐单抗联合化疗治疗。其中,贝伐单抗为美国综合癌症网指南推荐的5 mg/kg,每2周重复,观察临床疗效及相关的不良反应。结果该研究纳入的22例患者经过治疗,疾病的控制率为81.8%,而出现的毒副作用,主要是高血压、血尿及尿隐血阳性。结论对于晚期结直肠癌患者的治疗,采用贝伐单抗联合化疗治疗,具有疗效确切、不良反应少,且疾病控制率高等优点,值得在临床治疗中推广应用。

Objective To investigate the clinical effect of bevacizumab combined with chemotherapy in treatment of advanced col-orectal cancer and side effects. Methods Randomly selected patients with rectal cancer in 2010 October to 2014 July in our hospi-tal for treatment of advanced colorectal tissue or cell, bevacizumab for National Comprehensive Cancer Network guidelines recom-mend 5mg/kg, repeated every two weeks,. Results This study included 22 patients through the control treatment, the disease was 81.8%, and the emergence of side effects, mainly hypertension, hematuria and urinary occult blood positive. Conclusion For the treatment of advanced colorectal cancer patients, with bevacizumab combined with chemotherapy in the treatment of, has exact cu-rative effect, less adverse reaction, and the advantages of the high rate of disease control, is worthy to be popularized in clinical treatment.